1. Home
  2. BDL vs MAIA Comparison

BDL vs MAIA Comparison

Compare BDL & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Flanigan's Enterprises Inc.

BDL

Flanigan's Enterprises Inc.

HOLD

Current Price

$41.60

Market Cap

83.3M

ML Signal

HOLD

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

HOLD

Current Price

$1.38

Market Cap

79.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BDL
MAIA
Founded
1959
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
83.3M
79.0M
IPO Year
1995
2022

Fundamental Metrics

Financial Performance
Metric
BDL
MAIA
Price
$41.60
$1.38
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
37.9K
502.3K
Earning Date
05-18-2026
05-12-2026
Dividend Yield
1.90%
N/A
EPS Growth
49.72
33.33
EPS
1.98
N/A
Revenue
$205,248,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$21.09
N/A
Revenue Growth
8.99
N/A
52 Week Low
$26.33
$0.87
52 Week High
$47.99
$3.19

Technical Indicators

Market Signals
Indicator
BDL
MAIA
Relative Strength Index (RSI) 53.19 54.32
Support Level $29.15 $1.38
Resistance Level $47.99 $1.46
Average True Range (ATR) 3.02 0.06
MACD 0.26 0.02
Stochastic Oscillator 64.66 69.64

Price Performance

Historical Comparison
BDL
MAIA

About BDL Flanigan's Enterprises Inc.

Flanigan'S Enterprises Inc operates as a chain of small cocktail lounges and packages liquor stores throughout South Florida. The business activity is principally conducted in two segments namely Restaurant and Package liquor store segment. Its Restaurant segment offers alcoholic beverages and full food service, and Package stores consist of retail liquor sales and related items. Its menu consists of a wide variety of options including prime rib, steaks, pasta, entree salads, burgers, a variety of sandwiches, and oversized signature desserts. The company generates maximum revenue from Restaurant segment.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

Share on Social Networks: